Sugi Predict

Sugi Predict / Compounds / SCHEMBL1740290

SCHEMBL1740290

SCHEMBL1740290

c1ccc(C2CN(C(c3ccccc3)c3ccccc3)C2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ OPRM1 P35372 5/20 0.47
▸ CYP2D6 P10635 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ CHRM2 P08172 1/20 0.47
▸ CHRM4 P08173 1/20 0.47
▸ CHRM5 P08912 1/20 0.47
▸ ADRA2A P08913 1/20 0.47
▸ ADORA3 P0DMS8 1/20 0.47
▸ CHRM1 P11229 1/20 0.47
▸ CHRM3 P20309 1/20 0.47
▸ DRD1 P21728 1/20 0.47
▸ ADRA1D P25100 1/20 0.47
▸ HTR2A P28223 1/20 0.47
▸ HTR2C P28335 1/20 0.47
▸ HRH1 P35367 1/20 0.47
▸ DRD3 P35462 1/20 0.47
▸ HTR2B P41595 1/20 0.47
▸ SLC6A3 Q01959 1/20 0.47
▸ KCNH2 Q12809 1/20 0.47
▸ MEN1 O00255 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6980526 0.87 CYP2D6 (0.43) OPRM1CYP2D6KMT2ACHRM2CHRM4
SCHEMBL6774627 0.87 OPRM1 (0.48) OPRM1CYP2D6KMT2ACHRM2CHRM4
SCHEMBL6781064 0.87 CHRM2 (0.53) OPRM1CYP2D6KMT2ACHRM2ADRA2A
SCHEMBL6774278 0.83 MAOA (0.50) OPRM1CYP2D6KMT2ACHRM2CHRM4
SCHEMBL6774667 0.83 OPRM1 (0.50) OPRM1CYP2D6HTR2COPRL1OPRK1
SCHEMBL16225965 0.80 L3MBTL3 (0.59) OPRM1CYP2D6KMT2ACHRM2CHRM4
SCHEMBL17460137 0.79 SLC18A3 (0.57) CYP2D6KMT2AL3MBTL3L3MBTL1ALDH1A1
SCHEMBL6774815 0.79 SLC6A2 (0.42) CYP2D6CHRM2ADRA2ACHRM1DRD1
SCHEMBL6780265 0.79 OPRM1 (0.50) OPRM1CHRM2HTR2CDRD3HTR2B
SCHEMBL48800 0.77 OPRM1 (0.48) OPRM1CYP2D6KMT2ACHRM2CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1926710-A1 4-SUBSTITUTED PYRR0LIDIN-2-0NES AND THEIR USE UCB, S.A. (BE) 2008-06-04 — — EP claimed
WO-2007031263-A1 4-SUBSTITUTED PYRR0LIDIN-2-0NES AND THEIR USE UCB PHARMA, S.A. (BE) 2007-03-22 — — WO claimed
WO-2021124066-A1 PROCESS FOR THE PREPARATION OF BRIVARACETAM GLENMARK LIFE SCIENCES LIMITED (IN) 2021-06-24 — — WO disclosed
EP-3812377-A1 BRIVARACETAM INTERMEDIATE, PREPARATION METHOD THEREFOR, AND PREPARATION METHOD FOR BRIVARACETAM Shanghai Puyi Chemical Co., Ltd. (CN) 2021-04-28 — — EP disclosed
WO-2016014975-A2 UREA/CARBAMATES FAAH MAGL OR DUAL FAAH/MAGL INHIBITORS AND USES THEREOF NORTHEASTERN UNIVERSITY (US) 2016-01-28 — — WO disclosed
CN-102292340-B Amino-heterocyclic compounds used as pde9 inhibitors PFIZER 2015-05-06 — — CN disclosed
EP-1926710-B1 4-Substituted pyrrolidin-2-ones and their use UCB PHARMA SA (BE) 2014-11-12 — — EP disclosed
US-20140088081-A1 Amino-Heterocyclic Compounds PFIZER INC. (US) 2014-03-27 — — US disclosed
US-20140088081-A1 Amino-Heterocyclic Compounds PFIZER INC. (US) 2014-03-27 — — US disclosed
US-20140088081-A1 Amino-Heterocyclic Compounds PFIZER INC. (US) 2014-03-27 — — US disclosed
US-8618117-B2 Amino-heterocyclic compounds PFIZER INC. (US) 2013-12-31 — — US disclosed
US-20100190771-A1 AMINO-HETEROCYCLIC COMPOUNDS PFIZER INC. 2010-07-29 — — US disclosed
US-20100190771-A1 AMINO-HETEROCYCLIC COMPOUNDS PFIZER INC. 2010-07-29 — — US disclosed
US-20100190771-A1 AMINO-HETEROCYCLIC COMPOUNDS PFIZER INC. 2010-07-29 — — US disclosed
WO-2010084438-A1 AMINO-HETEROCYCLIC COMPOUNDS USED AS PDE9 INHIBITORS PFIZER INC. (US) 2010-07-29 — — WO disclosed
US-20080214520-A1 6-N-Linked Heterocycle-Substituted 2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists ELI LILLY AND COMPANY 2008-09-04 — — US disclosed
EP-1926710-A1 4-SUBSTITUTED PYRR0LIDIN-2-0NES AND THEIR USE UCB, S.A. (BE) 2008-06-04 — — EP disclosed
EP-1924578-A2 6-N-LINKED HETEROCYCLE-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2008-05-28 — — EP disclosed
WO-2007031263-A1 4-SUBSTITUTED PYRR0LIDIN-2-0NES AND THEIR USE UCB PHARMA, S.A. (BE) 2007-03-22 — — WO disclosed
WO-2007028132-A2 6-N-LINKED HETEROCYCLE-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2007-03-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214520-A1 6-N-Linked Heterocycle-Substituted 2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists HTR2C, HTR3B, HTR1A OPRM1 32/4885CYP2D6 217/4885KMT2A 1701/4885
US-20100190771-A1 AMINO-HETEROCYCLIC COMPOUNDS PDE9A, PDE2A, PDE10A OPRM1 3328/4885CYP2D6 1229/4885KMT2A 1487/4885
US-20140088081-A1 Amino-Heterocyclic Compounds PDE9A, PDE2A, PDE10A OPRM1 3328/4885CYP2D6 1229/4885KMT2A 1487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.